Letter from Aperio on Recent Sale

| August 27, 2012

Dear Aperio

On behalf of everyone at Aperio, I want to take
this opportunity to tell you about a new and exciting development. I am pleased
to announce that Leica Biosystems is acquiring Aperio. Aperio began as a
start-up business 12 years ago and today has grown into the leader of
ePathology solutions. By integrating with Leica Biosystems, we will improve our
global reach and provide the broadest portfolio of pathology solutions to serve
this growing and changing market.

At Aperio, we believe pathology plays a vital
role in patient care and research, with an ever-increasing importance due to
advances in diagnostic testing, more targeted drug therapy options, and
advances in personalized medicine. Leica Biosystems shares that belief.

Leica Biosystems’ goal is to provide solutions
that meet all your anatomical pathology needs and help advance cancer
diagnostics. They are represented in over 100 countries, with manufacturing
facilities in 7 countries, sales and service organizations in 19 countries, and
an international network of dealers. Leica Biosystems provides end-to-end
solutions that help customers improve workflow efficiency and diagnostic

Leica Biosystems is acquiring Aperio because of
our leadership in ePathology solutions, our great products, and our dedicated
team. We believe that together we can advance our product portfolio more
effectively, expand our global reach, and continue to improve our customer
service. The Aperio ePathology solutions are complementary to Leica’s own broad
portfolio of pathology solutions. The integrated business will enhance both
solutions going forward. For the foreseeable future we expect business to
remain as usual.

The transaction is subject to various closing
conditions, including customary regulatory approvals, and we will continue to
operate independently until the closing.

Please do not hesitate to contact me if you have any
. We look forward to continuing to serve you in the years
to come as Leica Biosystems and Aperio embark on this exciting new journey

Best regards, 

David Schlotterbeck 

CEO, Aperio


Category: Pathology News

Comments are closed.